Related Experiment Video
Updated: Jan 23, 2026
11:31
Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes
Published on: February 18, 2020
8.2K
Targeting BAX to drug death directly
1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Loren_Walensky@dfci.harvard.edu.
Nature Chemical Biology
|June 19, 2019
Summary
The BCL-2 protein family regulates apoptosis, crucial for tissue balance. New research identifies regulatory sites on BAX, enabling direct apoptosis modulation for disease treatment.
Area of Science:
- Molecular Biology
- Cellular Biology
- Biochemistry
Background:
- Apoptosis, or programmed cell death, is vital for tissue homeostasis.
- Dysregulation of apoptosis is implicated in various human diseases, including cancer.
- BCL-2 family proteins play a key role in regulating apoptosis.
Purpose of the Study:
- To explore the regulatory mechanisms of apoptosis.
- To identify potential targets for novel apoptosis modulators.
- To understand the 'inhibit the inhibitor' mechanism of Venetoclax.
Main Methods:
- Investigated BCL-2 family protein interactions.
- Analyzed the function of BCL-2 and BAX proteins.
- Identified physiologic and pharmacologic regulatory sites on BAX.
Main Results:
- Venetoclax, an FDA-approved drug, targets anti-apoptotic BCL-2 proteins.
- Venetoclax functions by blocking a key groove on BCL-2, disabling its inhibition of pro-apoptotic proteins.
- Multiple regulatory sites on BAX, a key executioner protein, have been identified.
Conclusions:
- The identified regulatory sites on BAX offer new therapeutic strategies.
- Direct modulation of BAX presents an alternative approach to targeting BCL-2.
- This research provides blueprints for developing novel apoptosis modulators for various diseases.
Related Concept Videos
01:26Targets for Drug Action: Overview
10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
01:30Overview of Cell Death
9.6K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
9.6K
01:18Autophagic Cell Death
4.4K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.4K
01:25Pharmacokinetics: Drug–Drug Interactions
394
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
394
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
154
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
154
01:26FDA Approved Drugs: Changes to Approved Drugs
248
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
248